These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 15679289)

  • 21. [Atorvastatin . A new generation of hypolipemic agents?].
    Azanza JR; Sádaba B; Quetglas EG
    Rev Med Univ Navarra; 1998; 42(1):51-5. PubMed ID: 10420957
    [No Abstract]   [Full Text] [Related]  

  • 22. [Prevention of cardiovascular diseases: Value of CSE inhibitors in the management of lipid metabolism disorders].
    Z Kardiol; 1998 Apr; 87(4 Suppl Stellenwer):1-4. PubMed ID: 9618894
    [No Abstract]   [Full Text] [Related]  

  • 23. Coronary revascularization and aggressive lipid lowering.
    Pershad A; Kratzer S; Cooper A
    J Invasive Cardiol; 1999 Feb; 11(2):87-9. PubMed ID: 10745488
    [No Abstract]   [Full Text] [Related]  

  • 24. Religious attendance: more cost-effective than lipitor?
    Denberg T
    J Am Board Fam Med; 2006; 19(4):430; author reply 431-3. PubMed ID: 16809663
    [No Abstract]   [Full Text] [Related]  

  • 25. Vascular protection of dual therapy (atorvastatin-amlodipine) in hypertensive patients.
    Martín-Ventura JL; Tuñon J; Duran MC; Blanco-Colio LM; Vivanco F; Egido J
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S189-93. PubMed ID: 17130260
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Fluvastatin in a comparative study. Are there substance-specific differences between various CSE-inhibitors?].
    Internist (Berl); 1999 Mar; 40(3 Suppl Gibt Es):1-4. PubMed ID: 10192028
    [No Abstract]   [Full Text] [Related]  

  • 27. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD; Rattinger GB; Kuznik A; Koren MJ
    Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential neurological value of statins increases.
    Bonetta L
    Nat Med; 2002 Jun; 8(6):541. PubMed ID: 12042786
    [No Abstract]   [Full Text] [Related]  

  • 29. Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
    Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):29-36. PubMed ID: 15703503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HMG CoA reductase inhibition and endothelial function in children with chronic kidney disease (CKD)--a pilot study.
    Mackie FE; Rosenberg AR; Harmer JA; Kainer G; Celermajer DS
    Acta Paediatr; 2010 Mar; 99(3):457-9. PubMed ID: 20050832
    [No Abstract]   [Full Text] [Related]  

  • 31. Design and rationale of a real-life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL study.
    Zamorano J; Erdine S; Lopez AP; Kim JH; Al Khadra A; Westergaard M; Sutradhar S; Yunis C;
    Postgrad Med; 2010 Mar; 122(2):7-15. PubMed ID: 20203451
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Coronary heart disease patient reaches LDL level of 100 mg/dl with atorvastatin: how do you continue treatment next year?].
    Weizel A; Sawicki PT
    MMW Fortschr Med; 2004 Dec; 146(51-52):14, 16. PubMed ID: 15675236
    [No Abstract]   [Full Text] [Related]  

  • 33. DUAAL: atorvastatin provided an unexpectedly potent heart benefit in patients with chronic stable angina.
    Cardiovasc J Afr; 2008; 19(3):174. PubMed ID: 18568187
    [No Abstract]   [Full Text] [Related]  

  • 34. A rationale for combination therapy in risk factor management: a mechanistic perspective.
    Mason RP
    Am J Med; 2005 Dec; 118 Suppl 12A():54-61. PubMed ID: 16356809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipid-lowering medications: what the new guidelines and data mean to women.
    Schwartz JB
    J Gend Specif Med; 2001; 4(2):9-13. PubMed ID: 11480105
    [No Abstract]   [Full Text] [Related]  

  • 36. Molecule of the month.
    Lindsley CW
    Curr Top Med Chem; 2008; 8(12):1100. PubMed ID: 18693392
    [No Abstract]   [Full Text] [Related]  

  • 37. Statins: not just for the young or the faint of heart.
    Coull BM; Johnston SC
    Neurology; 2009 Feb; 72(8):684-5. PubMed ID: 19237695
    [No Abstract]   [Full Text] [Related]  

  • 38. A retrospective analysis comparing the costs and cost effectiveness of amlodipine and enalapril in the treatment of hypertension.
    Doyle J; Omvik P; Arikian S; Casciano J; Casciano R; Gonzalez MA; Arocho R
    Manag Care Interface; 2001 Mar; 14(3):82-7. PubMed ID: 11301961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistant arterial hypertension and hyperlipidemia: atorvastatin, not vitamin C, for blood pressure control.
    Magen E; Viskoper R; Mishal J; Priluk R; Berezovsky A; Laszt A; London D; Yosefy C
    Isr Med Assoc J; 2004 Dec; 6(12):742-6. PubMed ID: 15609886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [What is new? Therapy with lipid lowering agents].
    Internist (Berl); 1997 Nov; 38(11 Suppl Therapie):1-8. PubMed ID: 9403084
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.